193 related articles for article (PubMed ID: 34740747)
1. P2Y12 inhibition in acute coronary syndromes treated with percutaneous intervention - Understanding the debate on Prasugrel or Ticagrelor.
Schäfer A; Bauersachs J
Pharmacol Ther; 2022 May; 233():108029. PubMed ID: 34740747
[TBL] [Abstract][Full Text] [Related]
2. Impact of Society Guidelines on Trends in Use of Newer P2Y
Mohamed MO; Kontopantelis E; Alasnag M; Abid L; Banerjee A; Sharp ASP; Bourantas C; Sirker A; Curzen N; Mamas MA
J Am Heart Assoc; 2024 May; 13(9):e034414. PubMed ID: 38700032
[TBL] [Abstract][Full Text] [Related]
3. NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View.
Angoulvant D; Sabouret P; Savage MP
Am J Cardiovasc Drugs; 2021 Sep; 21(5):483-486. PubMed ID: 33674980
[TBL] [Abstract][Full Text] [Related]
4. Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
Valina C; Neumann FJ; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Aytekin A; Richardt G; Witzenbichler B; Sibbing D; Cassese S; Angiolillo DJ; Kufner S; Liebetrau C; Hamm CW; Xhepa E; Hapfelmeier A; Sager HB; Wustrow I; Joner M; Trenk D; Laugwitz KL; Schunkert H; Schüpke S; Kastrati A
J Am Coll Cardiol; 2020 Nov; 76(21):2436-2446. PubMed ID: 33213722
[TBL] [Abstract][Full Text] [Related]
5. P2Y12 Inhibitors for Non-ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis.
Fujisaki T; Kuno T; Briasoulis A; Misumida N; Takagi H; Latib A
Tex Heart Inst J; 2023 May; 50(3):. PubMed ID: 37302149
[TBL] [Abstract][Full Text] [Related]
6. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
[TBL] [Abstract][Full Text] [Related]
7. Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Aytekin A; Ndrepepa G; Neumann FJ; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Lahu S; Richardt G; Witzenbichler B; Sibbing D; Cassese S; Angiolillo DJ; Valina C; Kufner S; Liebetrau C; Hamm CW; Xhepa E; Hapfelmeier A; Sager HB; Wustrow I; Joner M; Trenk D; Fusaro M; Laugwitz KL; Schunkert H; Schüpke S; Kastrati A
Circulation; 2020 Dec; 142(24):2329-2337. PubMed ID: 33115278
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of oral P2Y
Farmakis IT; Zafeiropoulos S; Doundoulakis I; Pagiantza A; Karagiannidis E; Moysidis DV; Stalikas N; Kassimis G; Michalis LK; Karvounis H; Giannakoulas G
Open Heart; 2022 Apr; 9(1):. PubMed ID: 35428703
[TBL] [Abstract][Full Text] [Related]
9. Real-World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome.
Yildirim M; Mueller-Hennessen M; Milles BR; Biener M; Hund H; Frey N; Giannitsis E; Salbach C
J Am Heart Assoc; 2023 Aug; 12(16):e030879. PubMed ID: 37581388
[TBL] [Abstract][Full Text] [Related]
10. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.
Schüpke S; Neumann FJ; Menichelli M; Mayer K; Bernlochner I; Wöhrle J; Richardt G; Liebetrau C; Witzenbichler B; Antoniucci D; Akin I; Bott-Flügel L; Fischer M; Landmesser U; Katus HA; Sibbing D; Seyfarth M; Janisch M; Boncompagni D; Hilz R; Rottbauer W; Okrojek R; Möllmann H; Hochholzer W; Migliorini A; Cassese S; Mollo P; Xhepa E; Kufner S; Strehle A; Leggewie S; Allali A; Ndrepepa G; Schühlen H; Angiolillo DJ; Hamm CW; Hapfelmeier A; Tölg R; Trenk D; Schunkert H; Laugwitz KL; Kastrati A;
N Engl J Med; 2019 Oct; 381(16):1524-1534. PubMed ID: 31475799
[TBL] [Abstract][Full Text] [Related]
11. Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes.
Husted S; Boersma E
Am J Ther; 2016; 23(6):e1876-e1889. PubMed ID: 25830867
[TBL] [Abstract][Full Text] [Related]
12. Prasugrel in the treatment of acute coronary syndrome.
Spartalis M; Tzatzaki E; Spartalis E; Paschou SA; Athanasiou A; Iliopoulos DC; Siasos G; Voudris V
Future Cardiol; 2020 Nov; 16(6):559-568. PubMed ID: 32390477
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial.
Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS
JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475
[TBL] [Abstract][Full Text] [Related]
14. [The ISAR-REACT 5 trial: is there a winner between prasugrel and ticagrelor in acute coronary syndromes?].
Ferlini M; Galvani M; Visconti LO
G Ital Cardiol (Rome); 2020 Mar; 21(3):171-174. PubMed ID: 32100728
[No Abstract] [Full Text] [Related]
15. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J
Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703
[TBL] [Abstract][Full Text] [Related]
16. Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes.
Wadowski PP; Weikert C; Pultar J; Lee S; Eichelberger B; Koppensteiner R; Lang IM; Panzer S; Gremmel T
Cardiovasc Drugs Ther; 2020 Feb; 34(1):53-63. PubMed ID: 32062795
[TBL] [Abstract][Full Text] [Related]
17. Ticagrelor Utilization in Patients With Non-ST Elevation Acute Coronary Syndromes in Romania.
Cotoban AG; Udroiu CA; Vinereanu D
Am J Ther; 2021 Apr; 28(3):e271-e283. PubMed ID: 33852478
[TBL] [Abstract][Full Text] [Related]
18. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.
Kamran H; Jneid H; Kayani WT; Virani SS; Levine GN; Nambi V; Khalid U
JAMA; 2021 Apr; 325(15):1545-1555. PubMed ID: 33877270
[TBL] [Abstract][Full Text] [Related]
19. Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
Joshi RR; Hossain R; Morton AC; Ecob R; Judge HM; Wales C; Walker JV; Karunakaran A; Storey RF
Platelets; 2014; 25(6):416-22. PubMed ID: 24111601
[TBL] [Abstract][Full Text] [Related]
20. Comparison of prasugrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized and non-randomized studies.
Watti H; Dahal K; Zabher HG; Katikaneni P; Modi K; Abdulbaki A
Int J Cardiol; 2017 Dec; 249():66-72. PubMed ID: 29121759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
